Surrozen, Inc. (NASDAQ:SRZN) Short Interest Update

Surrozen, Inc. (NASDAQ:SRZN) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totalling 36,200 shares, a growth of 358.2% from the March 31st total of 7,900 shares. Approximately 1.9% of the company’s shares are sold short. Based on an average daily volume of 16,700 shares, the days-to-cover ratio is currently 2.2 days.

Insider Activity

In other Surrozen news, Director Tim Kutzkey bought 193,548 shares of Surrozen stock in a transaction on Thursday, April 4th. The shares were purchased at an average cost of $15.50 per share, with a total value of $2,999,994.00. Following the acquisition, the director now directly owns 332,885 shares of the company’s stock, valued at approximately $5,159,717.50. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 35.00% of the company’s stock.

Hedge Funds Weigh In On Surrozen

A hedge fund recently raised its stake in Surrozen stock. Euclidean Capital LLC grew its position in shares of Surrozen, Inc. (NASDAQ:SRZN) by 63.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,315,463 shares of the company’s stock after purchasing an additional 512,500 shares during the quarter. Surrozen comprises approximately 0.1% of Euclidean Capital LLC’s investment portfolio, making the stock its 12th largest position. Euclidean Capital LLC owned approximately 64.48% of Surrozen worth $645,000 at the end of the most recent reporting period. 66.57% of the stock is currently owned by institutional investors.

Surrozen Stock Up 4.3 %

SRZN traded up $0.37 during midday trading on Friday, hitting $8.98. 11,126 shares of the company were exchanged, compared to its average volume of 27,275. The firm’s 50 day moving average price is $12.07 and its 200-day moving average price is $9.32. Surrozen has a 1-year low of $4.50 and a 1-year high of $16.19. The firm has a market capitalization of $28.73 million, a P/E ratio of -0.52 and a beta of 0.74.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.